New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
10:35 EDTNBR, IPG, SNV, NI, CYTR, HZNPHigh option volume stocks: HZNP NI IPG CYTR SNV NBR
News For HZNP;NI;IPG;CYTR;SNV;NBR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
11:50 EDTNBRStocks with call strike movement; RIG NBR
Subscribe for More Information
January 23, 2015
10:15 EDTNBROptions with decreasing implied volatility
Subscribe for More Information
08:37 EDTNBRBofA/Merrill U.S. oil & gas analysts to hold an analyst/industry conference call
Subscribe for More Information
January 22, 2015
10:35 EDTNBROptions with decreasing implied volatility
Options with decreasing implied volatility: CZR ACHN NFLX SN NBR TLM CREE BBY LNCO BBRY
09:34 EDTCYTRCytRx to host conference call
Subscribe for More Information
09:09 EDTCYTRCytRx's Aldoxorubicin shows positive Phase 2b results for soft tissue sarcoma
CytRx reported positive overall survival results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas. The OS results in 123 patients demonstrated that aldoxorubicin-treated patients demonstrated a 27% reduction in the risk of death compared to patients treated with doxorubicin, the current standard-of-care in this indication.In addition, aldoxorubicin-treated patients demonstrated a 41% likelihood of surviving more than 2 years, a 2-fold increase, compared to a 20% probability for doxorubicin-treated patients. Median overall survival was 16.0 months for aldoxorubicin-treated patients versus 14.4 months for doxorubicin treated patients. For treatment-naive patients, representing 90% of the patients in the clinical trial, median overall survival was 16.0 months for aldoxorubicin-treated patients versus 14.0 months for doxorubicin treated patients. The positive trend could be significantly improved, now that the FDA has permitted CytRx to dose aldoxorubicin in all trials until tumor progression.
January 21, 2015
11:36 EDTNBRStocks with call strike movement; NBR RIG
Nabors Industries (NBR) June 12 call option implied volatility decreased 4% to 65, Transocean (RIG) August 19 call option implied volatility decreased 8% to 67 according to IVolatility.
10:01 EDTHZNPOn the Fly: Analyst Initiation Summary
Subscribe for More Information
10:01 EDTNBROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:53 EDTNBRNabors Industries downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
06:08 EDTHZNPHorizon Pharma initiated with a Buy at Citigroup
Subscribe for More Information
January 20, 2015
09:11 EDTCYTROn The Fly: Pre-market Movers
Subscribe for More Information
06:06 EDTCYTRFDA removes partial clinical hold for CytRx's aldoxorubicin clinical trials
CytRx announced that the FDA has removed the partial clinical hold on the Company's aldoxorubicin clinical trials. Enrollment and dosing of new patients is now permitted after study sites' Institutional Review Boards approve the revised trial protocols. CytRx currently believes that enrollment rates and timelines for its trials will remain materially unchanged. The Company expects to complete enrollment in its ongoing pivotal global Phase 3 trial in second-line soft tissue sarcoma by the end of 2015 and unblind the clinical data by mid-2016. Subject to FDA approval, CytRx's market launch of aldoxorubicin for second line soft tissue sarcoma is projected to commence in 2017.
January 15, 2015
10:00 EDTHZNPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:14 EDTHZNPHorizon Pharma initiated with a Buy at UBS
Subscribe for More Information
January 13, 2015
16:03 EDTIPGMcCann Worldgroup Detroit appoints Lance Miller as Chief Technology Officer
McCann Worldgroup Detroit announced that Lance Miller has been named Chief Technology Officer. Miller will lead the IT department, oversee the integration of existing and emerging technologies and build a cohesive infrastructure for the Worldgroup Detroit teams, Commonwealth//McCann global operations and their respective clients. Miller joins the company after serving as Director of Client Services for Southfield, Michigan-based UltraLevel, where he oversaw the Professional Services, Managed Services and Learning Services business units. Prior to that, he spent four years at MRM//McCann. McCann Worldgroup is part of the Interpublic Group.
10:27 EDTNBRStocks with call strike movement; RIG NBR
Transocean (RIG) May 19 call option implied volatility decreased 3% to 72, Nabors Industries (NBR) June 13 call option implied volatility increased 2% to 69 according to IVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use